EGFR and non-small cell lung carcinoma: Nevertheless, a tertiary mutation in EGFR C797S caused inevitable Osimertinib resistance, which significantly reduced the therapeutic effect during treatment of NSCLC and resulted in the requirement of developing novel inhibitors that target EGFRC797S [11].